MMP-7 marks severe pancreatic cancer and alters tumor cell signaling by proteolytic release of ectodomains.

ABSTRACT: Pancreatic cancer incurs the worst survival rate of the major cancers. High levels of the protease matrix metalloproteinase-7 (MMP-7) in circulation correlate with poor prognosis and limited survival of patients. MMP-7 is required for a key path of pancreatic tumorigenesis in mice and is present throughout tumor progression. Enhancements to chemotherapies are needed for increasing the number of pancreatic tumors that can be removed and for preventing relapses after surgery. With these ends in mind, selective inhibition of MMP-7 may be worth investigation. An anti-MMP-7 monoclonal antibody was recently shown to increase the susceptibility of several pancreatic cancer cell lines to chemotherapeutics, increase their apoptosis, and decrease their migration. MMP-7 activities are most apparent a

SUBMITTER: Van Doren SR 

PROVIDER: S-EPMC10443904 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature